Dogwood Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-34.3M | $-12.3M | $-5.3M | $-12.2M | $-16.0M | $-10.3M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $2.1K | $12.2K | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $355.6K | $476.0K | $620.0K | $582.7K | $322.9K | $7.4M |
| Net Cash from Operating Activities | $-15.6M | $-8.8M | $-4.9M | $-11.5M | $-15.7M | $-3.9M |
| Investing Activities | ||||||
| Capital Expenditures | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $3.8M | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $7.3M | $16.7M | $1.2M | $4.5M | $-97.6K | $33.4M |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — |